Brivaracetam has been developed to have less interactions and be more specific in partial and generalized seizuresIts relatively favourable profile in animal models of memoryis likely to result in comparative trials in neurodegenerative conditions associated with secondary epilepsy.
- Oral adult dose typically 50-100mg a day, up to 200mg/day
Cautions and Interactions
- Somnolence (> 14%)
There are four stereoisomers. It is a high-affinity ligand of the synaptic vesicle protein 2A, and 10-30 fold more potent than levetiracetam. However it does not share levetiracetam's inhibitory activity on the high voltage Ca2+ channels and AMPA receptors. Brivaracetam may act as a partial antagonist on neuronal voltage-gated sodium channels.
- ↑ Ferlazzo E, Russo E, Mumoli L, Sueri C, Gasparini S, Palleria C, Labate A, Gambardella A, De Sarro G, Aguglia U. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatric disease and treatment. 2015; 11:2967-73.(Epub) (Link to article – subscription may be required.)
- ↑ Detrait ER, Leclercq K, Löscher W, Potschka H, Niespodziany I, Hanon E, Kaminski RM, Matagne A, Lamberty Y. Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. Epilepsy research. 2010 Sep; 91(1):74-83.(Link to article – subscription may be required.)
- ↑ Qiu S, Tehrani KA, Sergeyev S, Bultinck P, Herrebout W, Mathieu B. Stereochemistry of the Brivaracetam Diastereoisomers. Chirality. 2016 Jan 6.(Epub ahead of print) (Link to article – subscription may be required.)